Skip to main content
Have a personal or library account? Click to login
Fibulin-3 as a biomarker of response to treatment in malignant mesothelioma Cover

Fibulin-3 as a biomarker of response to treatment in malignant mesothelioma

Radiology and Oncology
Volume 49 (2015): Issue 3 (September 2015)
By: ,  ,  ,   and    
Open Access
|Aug 2015
References

References

  1. 1. Berry M. Mesothelioma incidence and community asbestos exposure.1997;34-40.
    Open DOISearch in Google Scholar
  2. 2. Iwatsubo Y, Pairon JC, Boutin C, Menard O, Massin N, Caillaud D, et al. Pleural mesothelioma: dose-response relation at low levels of asbestos exposure in a French population-based case-control study.iol 1998;133-42.
    Open DOISearch in Google Scholar
  3. 3. Howel D, Gibbs A, Arblaster L, Swinburne L, Schweiger M, Renvoize E, et al. Mineral fibre analysis and routes of exposure to asbestos in the development of mesothelioma in an English region.1999;51-8.
    Open DOISearch in Google Scholar
  4. 4. Agudo A, González CA, Bleda MJ, Ramirez J, Hernandez S, Lopez F, et al. Occupation and risk of malignant pleural mesothelioma: a case-control study in Spain.2000;159-68.
    Open DOISearch in Google Scholar
  5. 5. Magnani C, Dalmasso P, Biggeri A, Ivaldi C, Mirabelli D, Terracini B. Increased risk of malignant mesothelioma of the pleura after residential or domestic exposure to asbestos: a case-control study in Casale Monferrato, Italy.2001;915-9.
    Open DOISearch in Google Scholar
  6. 6. Zellos L, Christiani DC. Epidemiology, biologic behaviour, and natural history of mesothelioma.2004;469-77.
    Open DOISearch in Google Scholar
  7. 7. Pan XL, Day HW, Wang W, Beckett LA, Schenker MB. Residential proximity to naturally occurring asbestos and mesothelioma risk in California.2005;1019-25.
    Open DOISearch in Google Scholar
  8. 8. Maule MM, Magnani C, Dalmasso P. Modeling mesothelioma risk associated with environmental asbestos exposure.2007;1066-71.
    Open DOISearch in Google Scholar
  9. 9. Robinson BW, Lake RA. Advances in malignant mesothelioma.2005;1591-603.
    Open DOISearch in Google Scholar
  10. 10. Kovac V, Zwitter M, Zagar T. Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: population-based survey of 444 patients.2012;136-44.
    Open DOISearch in Google Scholar
  11. 11. Hollevoet K, Reitsma JB, Creaney J, Grigoriu BD, Robinson BW, Scherpereel A, et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.2012;1541-9.
    Open DOISearch in Google Scholar
  12. 12. Franko A, Dolzan V, Kovac V, Arneric N, Dodic-Fikfak M. Soluble mesothelin-related peptides levels in patients with malignant mesothelioma.2012;123-31.
    Open DOISearch in Google Scholar
  13. 13. Pass HI, Levin SM, Harbut MR, Melamed J, Chiriboga L, Donington J, et al. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma.2012;1417-27.
    Open DOISearch in Google Scholar
  14. 14. Timpl R, Sasaki T, Kostka G, Chu ML. Fibulins: a versatile family of extracellular matrix proteins.2003;479-89.
    Open DOISearch in Google Scholar
  15. 15. Argraves WS, Greene LM, Cooley MA, Gallagher WM. Fibulins: physiological and disease perspectives.2003;1127-31.
    Open DOISearch in Google Scholar
  16. 16. Zhang Y, Marmorstein LY. Focus on molecules: fibulin-3 (EFEMP1).2010;374-5.
    Open DOISearch in Google Scholar
  17. 17. Kim IG, Kim SY, Choi SI, Lee JH, Kim KC, Cho EW. Fibulin-3-mediated inhibition of epithelial-to-mesenchymal transition and self-renewal of ALDH+ lung cancer stem cells through IGF1R signaling.2014;3908-17.
    Open DOISearch in Google Scholar
  18. 18. Kobayashi N, Kostka G, Garbe JH, Keene DR, Bachinger HP, Hanisch FG, et al. A comparative analysis of the fibulin protein family. Biochemical characterization, binding interactions, and tissue localization.2007;11805-16.
    Open DOISearch in Google Scholar
  19. 19. Yue W, Dacic S, Sun Q, Landreneau R, Guo M, Zhou W, et al. Frequent inactivation of RAMP2, EFEMP1 and Dutt1 in lung cancer by promoter hypermethylation.2007;4336-44.
    Open DOISearch in Google Scholar
  20. 20. Xu S, Yang Y, Sun YB, Wang HY, Sun CB, Zhang X. Role of fibulin-3 in lung cancer: in vivo and in vitro analyses.2014;79-86.
    Open DOISearch in Google Scholar
  21. 21. Sadr-Nabavi A, Ramser J, Volkmann J, Naehrig J, Wiesmann F, Betz B, et al. Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker.2009;1727-35.
    Open DOISearch in Google Scholar
  22. 22. Nomoto S, Kanda M, Okamura Y, Nishikawa Y, Qiyong L, Fujii T, et al. Epidermal growth factor-containing fibulin-like extracellular matrix protein 1, EFEMP1, a novel tumor-suppressor gene detected in hepatocellular carcinoma using double combination array analysis.2010;923-32.
    Open DOISearch in Google Scholar
  23. 23. Hu B, Thirtamara-Rajamani KK, Sim H, Viapiano MS. Fibulin-3 is uniquely upregulated in malignant gliomas and promotes tumor cell motility and invasion.2009;1756-70.
    Open DOISearch in Google Scholar
  24. 24. En-lin S, Sheng-guo C, Hua-qiao W. The expression of EFEMP1 in cervical carcinoma and its relationship with prognosis.2010;417-22.
    Open DOISearch in Google Scholar
  25. 25. Seeliger H, Camaj P, Ischenko I, Kleespies A, De Toni EN, Thieme SE, et al. EFEMP1 expression promotes in vivo tumor growth in human pancreatic adenocarcinoma.2009;189-98.
    Open DOISearch in Google Scholar
  26. 26. Creaney J, Dick IM, Meniawy TM, Leong SL, Leon JS, Demelker Y, et al. Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma.2014;895-902.
    Open DOISearch in Google Scholar
  27. 27. UICC International Union Against Cancer. Pleurak mesothelioma. In: Sobin LH, Gospodarowicz MK, Wittekind C, editors., 7edition. Chichester: Wiley-Blackwell; 2009. p. 147-50.
    Search in Google Scholar
  28. 28. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.2004;257-60.
    Open DOISearch in Google Scholar
  29. 29. Podobnik J, Kocijancic I, Kovac V, Sersa I. 3T MRI in evaluation of asbestos-related thoracic diseases - preliminary results.2010;92-6.
    Open DOISearch in Google Scholar
  30. 30. Zwitter M, Stanic K, Rajer M, Kern I, Vrankar M, Edelbaher N, et al. Intercalated chemotherapy and erlotinib for advanced NSCLC: high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutations.2014;361-8.
    Open DOISearch in Google Scholar
  31. 31. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.2003;2636-44.
    Open DOISearch in Google Scholar
  32. 32. Goricar K, Kovac V, Dolzan V. Polymorphisms in folate pathway and pemetrexed treatment outcome in patients with malignant pleural mesothelioma.2014;163-72.
    Open DOISearch in Google Scholar
  33. 33. Lee CW, Murray N, Anderson H, Rao SC, Bishop W. Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: A review of practice in British Columbia.2009;: 308-13.
    Open DOISearch in Google Scholar
  34. 34. Kovac V, Zwitter M, Rajer M, Marin A, Debeljak A, Smrdel U, et al. A phase II trial of low-dose gemcitabine in prolonged infusion and cisplatin for malignant pleural mesothelioma.2012;230-8.
    Open DOISearch in Google Scholar
  35. 35. Ferris BG. Epidemiology Standardization Project (American Thoracic Society).1978;1-20.
    Search in Google Scholar
  36. 36. Dodic Fikfak M, Kriebel D, Quinn MM, Eisen EA, Wegman DH. A case control study of lung cancer and exposure to chrysotile and amphibole at a Slovenian asbestos-cement plant.2007;261-8.
    Search in Google Scholar
DOI: https://doi.org/10.1515/raon-2015-0019 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Journal RSS Feed
Language: English
Page range: 279 - 285
Submitted on: Mar 16, 2015
Accepted on: Mar 30, 2015
Published on: Aug 21, 2015
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
fibulin-3,
biomarker,
malignant mesothelioma,
response to treatment
Related subjects:
Medicine,
Clinical medicine,
Radiology

© 2015 Viljem Kovac, Metoda Dodic-Fikfak, Niko Arneric, Vita Dolzan, Alenka Franko, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Volume 49 (2015): Issue 3 (September 2015)
Previous article
Next article